Enlivex Therapeutics (ENLV) Competitors $0.98 -0.05 (-4.87%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ENLV vs. GNLX, ME, CASI, FBLG, PMVP, ONCY, IKNA, QNCX, CLSD, and CMRXShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Genelux (GNLX), 23andMe (ME), CASI Pharmaceuticals (CASI), FibroBiologics (FBLG), PMV Pharmaceuticals (PMVP), Oncolytics Biotech (ONCY), Ikena Oncology (IKNA), Quince Therapeutics (QNCX), Clearside Biomedical (CLSD), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Genelux 23andMe CASI Pharmaceuticals FibroBiologics PMV Pharmaceuticals Oncolytics Biotech Ikena Oncology Quince Therapeutics Clearside Biomedical Chimerix Genelux (NASDAQ:GNLX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Do analysts prefer GNLX or ENLV? Genelux presently has a consensus target price of $18.25, suggesting a potential upside of 632.93%. Enlivex Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 514.75%. Given Genelux's higher possible upside, research analysts plainly believe Genelux is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has stronger valuation & earnings, GNLX or ENLV? Genelux has higher revenue and earnings than Enlivex Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$170K505.91-$28.30M-$0.95-2.62Enlivex TherapeuticsN/AN/A-$29.07M-$1.18-0.83 Which has more volatility & risk, GNLX or ENLV? Genelux has a beta of -1.85, meaning that its share price is 285% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Is GNLX or ENLV more profitable? Enlivex Therapeutics' return on equity of -71.76% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -105.05% -80.16% Enlivex Therapeutics N/A -71.76%-60.78% Does the MarketBeat Community believe in GNLX or ENLV? Enlivex Therapeutics received 39 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 79.10% of users gave Enlivex Therapeutics an outperform vote. CompanyUnderperformOutperformGeneluxOutperform Votes14100.00% Underperform VotesNo VotesEnlivex TherapeuticsOutperform Votes5379.10% Underperform Votes1420.90% Does the media prefer GNLX or ENLV? In the previous week, Genelux had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for Genelux and 4 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.31 beat Genelux's score of -0.56 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Enlivex Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of GNLX or ENLV? 37.3% of Genelux shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 9.3% of Genelux shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryGenelux and Enlivex Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.05M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-0.835.5697.3414.18Price / SalesN/A348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book0.607.885.805.12Net Income-$29.07M$153.61M$119.07M$225.99M7 Day Performance-9.63%-2.00%-1.83%-1.32%1 Month Performance-36.21%-7.47%-3.64%0.60%1 Year Performance-44.23%31.80%31.62%26.23% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.0768 of 5 stars$0.98-4.9%$6.00+514.8%-42.9%$22.05MN/A-0.8370News CoverageGap UpHigh Trading VolumeGNLXGenelux1.3298 of 5 stars$2.49+0.4%$18.25+632.9%-76.8%$85.65M$170,000.000.0010Gap UpME23andMe1.1142 of 5 stars$3.15-8.2%$9.40+198.4%-82.6%$84.08M$219.64M0.00770CASICASI Pharmaceuticals3.7991 of 5 stars$5.22-2.2%$6.00+14.9%+0.4%$82.56M$33.88M0.00180FBLGFibroBiologics1.729 of 5 stars$2.24-5.9%$12.00+435.7%N/A$82.49MN/A0.0010PMVPPMV Pharmaceuticals2.804 of 5 stars$1.57-1.3%$5.80+269.4%-36.9%$82.28MN/A0.0050ONCYOncolytics Biotech1.2173 of 5 stars$1.00-5.7%$4.00+300.6%-37.2%$81.70MN/A0.0030Analyst RevisionIKNAIkena Oncology3.4984 of 5 stars$1.70+1.2%$3.00+76.5%-0.6%$81.07M$9.16M0.0070QNCXQuince Therapeutics2.8745 of 5 stars$1.84+4.0%$8.50+362.0%+109.1%$80.96MN/A-1.4860CLSDClearside Biomedical3.0244 of 5 stars$1.05+1.9%$5.33+407.9%+8.1%$79.63M$8.23M-2.2930Analyst RevisionCMRXChimerix4.5147 of 5 stars$0.88flat$8.50+865.9%-12.0%$79.15M$320,000.00-0.9472Analyst Forecast Related Companies and Tools Related Companies GNLX Competitors ME Competitors CASI Competitors FBLG Competitors PMVP Competitors ONCY Competitors IKNA Competitors QNCX Competitors CLSD Competitors CMRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENLV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENLV Stock Alerts